Literatur
Dufrost V, Risse J, Reshetnyak T, Satybaldyeva M, Du Y, Yan XX, Salta S, Gerotziafas G, Jing ZC, Elalamy I, Wahl D, Zuily S (2018) Increased risk of thrombosis in antiphospholipid syndrome patients treated with direct oral anticoagulants. Results from an international patient-level data meta-analysis. Autoimmun Rev 17(10):1011–1021. https://doi.org/10.1016/j.autrev.2018.04.009
Cohen H, Hunt BJ, Efthymiou M, Arachchillage DR, Mackie IJ, Clawson S, Sylvestre Y, Machin SJ, Bertolaccini ML, Ruiz-Castellano M, Muirhead N, Doré CJ, Khamashta M, Isenberg DA (2016) RAPS trial investigators. Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial. Lancet Haematol 3(9):e426–e436. https://doi.org/10.1016/S2352-3026
Pengo V, Denas G, Zoppellaro G, Jose SP, Hoxha A, Ruffatti A, Andreoli L, Tincani A, Cenci C, Prisco D, Fierro T, Gresele P, Cafolla A, De Micheli V, Ghirarduzzi A, Tosetto A, Falanga A, Martinelli I, Testa S, Barcellona D, Gerosa M, Banzato A (2018) Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood 132(13):1365–1371. https://doi.org/10.1182/blood-2018-04-848333
Tektonidou MG, Andreoli L, Limper M, Amoura Z, Cervera R, Costedoat-Chalumeau N, Cuadrado MJ, Dörner T, Ferrer-Oliveras R, Hambly K, Khamashta MA, King J, Marchiori F, Meroni PL, Mosca M, Pengo V, Raio L, Ruiz-Irastorza G, Shoenfeld Y, Stojanovich L, Svenungsson E, Wahl D, Tincani A, Ward MM (2019) EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis. https://doi.org/10.1136/annrheumdis-2019-215213
Woller SC, Stevens SM, Kaplan DA, Rondina TM (2018) Protocol modification of apixaban for the secondary prevention of thrombosis among patients with antiphospholipid syndrome study. Clin Appl Thromb Hemost 24(1):192. https://doi.org/10.1177/1076029617729214
Cortés-Hernández J, Sáez-Comet L, Riera Mestre A, Castro Salomó A, Cuquet Pedragosa J, Ortiz-Santamaría V, Mauri Plana M, Ordi-Ros J (2018) Rivaroxaban versus warfarin as secondary thromboprophylaxis in patients with antiphospholipid syndrome: a randomized, multicenter, open-label, clinical trial [abstract #174. Arthritis Rheumatol 70(suppl 10)
https://www.akdae.de/Arzneimittelsicherheit/DSM/Archiv/2019-31.html. Zugegriffen: 27.05.2019
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Interessenkonflikt
C. Specker, T. Dörner und M. Schneider geben an, dass kein Interessenkonflikt besteht.
Additional information
Redaktion
U. Müller-Ladner, Bad Nauheim
U. Lange, Bad Nauheim
Rights and permissions
About this article
Cite this article
Specker, C., Dörner, T. & Schneider, M. Hot Topic: Direkte orale Antikoagulanzien (DOACs) beim Antiphospholipidsyndrom?. Z Rheumatol 78, 493–494 (2019). https://doi.org/10.1007/s00393-019-0657-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00393-019-0657-0